Key result
Pioglitazone daily increased adiponectin levels from 10.6 to 21.1 microg/ml and improved ED-FMD from 4.45% to 8.43% in nondiabetic patients with stable CAD.
Why the study?
Does pioglitazone improve adiponectin levels and endothelial function in nondiabetic patients with stable coronary artery disease?
Does pioglitazone improve adiponectin levels and endothelial function in nondiabetic patients with stable coronary artery disease?
Pioglitazone significantly improves adiponectin levels and endothelial function in nondiabetic patients with stable coronary artery disease, suggesting potential cardiovascular benefits beyond glycemic control.
Answers are grounded in this paper and cite their sources.
May improve endothelial function in nondiabetic stable CAD; hypothesis-generating and requires RCTs before practice change.
OBJECTIVES: Hypoadiponectinemia is associated with coronary artery disease (CAD). Pioglitazone has been shown to increase levels of adiponectin in diabetic patients. We sought to assess whether administration of pioglitazone to patients with CAD and without diabetes would affect plasma adiponectin levels and endothelial function. METHODS: Seventeen patients with stable CAD and without evidence of diabetes were treated for 12 weeks with pioglitazone hydrochloride 30 mg daily. Adiponectin levels and endothelium-dependent flow-mediated vasodilation (ED-FMD) measurements were obtained pretreatment, posttreatment, and after a 12-week washout period. RESULTS: Treatment with pioglitazone increased adiponectin levels from an average of 10.6 to 21.1 microg/ml (P=0.001) and improved ED-FMD from 4.45 to 8.43% (P=0.001). CONCLUSION: Treatment with pioglitazone increased plasma adiponectin levels and improved ED-FMD in patients with stable CAD and no evidence of diabetes or insulin resistance.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2008) studied Coronary artery disease (n=17). Pioglitazone hydrochloride vs. Pretreatment baseline was evaluated on Plasma adiponectin levels (microg/ml) (p=0.001). Pioglitazone daily increased adiponectin levels from 10.6 to 21.1 microg/ml and improved ED-FMD from 4.45% to 8.43% in nondiabetic patients with stable CAD.
Synapse has enriched 10 related papers. Consider them for comparative context: